Moneycontrol PRO
UPCOMING EVENT:Know how Global Investing can be spread beyond the US markets by joining an engaging webinar on November 30, 11:30 a.m.

Stellar rally! More than 180 stocks outperform Nifty; rose over 13-40% in 3 days

The Nifty mid-cap, small-cap behaved in tandem with benchmarks as it rallied over 7 percent, each. Sectorally, all major indices ended in green led by auto, pharma, and financials

April 11, 2020 / 10:09 AM IST

It was exciting three days as bulls helped the S&P BSE Sensex, and Nifty50 climb key resistance levels. Investors’ wealth rose by over Rs 12 lakh crore in a truncated week.

Both Sensex and Nifty50 rallied by about 13 percent for the week ended April 9 while the broader markets underperformed as the S&P BSE Mid-cap index was up 11.3 percent, and the S&P BSE Smallcap index closed 9.4 percent higher.

There are as many as 186 stocks in the S&P BSE 500 index which outperformed Nifty50. These included names such as Care Ratings, Balkrishna Industries, Shipping Corp, Natco Pharma, Dabur India, Tata Motors, Apollo Tyres, Dr Reddy’s Laboratories, Dish TV, TCS, Ipca Laboratories, Titan Company, and JSPL among others.

There are nearly 300 stocks in the S&P BSE Small-cap index which rose more than 13 percent in three trading sessions. These include Sintex Industries, VA Tech Wabag, Uniply Industries, Jyothy Labs, JK Paper, and Manali Petro among others.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Note: Here is a list of top 100 stocks from 186 based on returns in the week gone by. The list is for reference only and not buy or sell ideas.

Weekly 1

Weekly 2

Positive global cues helped bulls to fuel a massive short-covering rally on D-Street. Foreign institutional investors who were net sellers in March and most part of April also turned net buyers in the last three sessions pouring over Rs 4,000 crores.

Expectations of further stimulus measures from the government, fall in new cases of COVID-19 in the United States as well as Europe, and expectations of smart money moving towards India post-MSCI rejig helped the sentiment.

"The benchmark indices ended with a positive note with an expectation of stimulus package from the government. The number of COVID-19 cases in India is low compare to the other nations like US and European countries like Italy, Spain where the number of deaths is in thousands as compared to the hundreds in India," Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor told Moneycontrol.

"Although the government has announced various relief measures to save the economy, investors are still expecting a second stimulus package from the government which might be focused on MSMEs which is the worst hit," he said.

The coming week will be an interesting one as the initial lockdown period will come to an end. But, initial reports suggest that this period is likely to get extended.

On the macro front, inflation data will be eyed and a further stimulus from the govt. to boost the economy or support the MSME sector will lift sentiments.

"This uptrend seems to be a short term bear market rally and may not be sustainable. In India, there is an expectation that the worst affected sectors and MSMEs may get some relief in another package to be announced shortly," Vinod Nair, Head of Research at Geojit Financial told Moneycontrol.

"Markets will continue to fluctuate based on news coming out regarding the spread of infections and any lifting of lockdown in India," he said.

Technical Outlook:

Equity benchmarks settled the truncated week on a cheerful note underpinned by firm global cues. The Nifty50 closed the week at 9,111, up by 12.7 percent.

The Nifty Mid-cap, small-cap behaved in tandem with benchmarks as it rallied over 7 percent, each. Sectorally, all major indices ended in green led by auto, pharma, and financials.

The weekly price action formed a sizable bull candle carrying higher high-low after seven weeks decline, indicating a pause in the corrective phase.

Any cool off from hereon due to elevated global volatility would get anchored around 8,500 as it is 61.8 percent retracement of last three session sharp up move (8,055 – 9,132), at 8,466, suggest experts.

“In the process, index surpassed intermediate resistance of 9,000, on expected lines, signifying acceleration of upward momentum towards 9,500 in coming weeks, Dharmesh Shah, Head – Technical, ICICI direct told Moneycontrol.

“Hence, the near term breather towards 8,500 should not be construed as negative, instead it should be capitalised as an incremental buying opportunity in the upcoming truncated week,” he said.

Disclaimer: The views and investment tips expressed by investment experts on are their own and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Kshitij Anand is the Editor Markets at Moneycontrol.

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark